Our previous studies have confirmed that the inhibitory effect of orally administered ciclamilast on airway hyperresponsiveness is due to its inhibition of PDE4 expression, upregulation of cAMP-PDE activity, and downmodulation of PDE4 activity. Here, PDE4A is linked to airway hyperresponsiveness.